Analyst Downgrades Immunic After Lack of Details Drive Uncertainty – Immunic (NASDAQ:IMUX)
[ad_1] SVB Leerink has downgraded Immunic Inc IMUX to Market Perform from Outperform following disappointing initial data from the highly anticipated Phase 1b proof-of-concept study for IMU-935 in patients with moderate-to-severe psoriasis. The analyst…
Walmart Coughs Up $215M To Resolve Opioid Lawsuits In Florida – Walmart (NYSE:WMT)
[ad_1] Walmart Inc WMT will pay $215 million to resolve its opioid-related in Florida. As part of the deal, Walmart has also agreed to dispense 672,000 treatment kits with the…
Why Immunic (IMUX) Shares Are Slumping Today – Immunic (NASDAQ:IMUX)
[ad_1] Immunic Inc IMUX announced the outcome of a pre-planned interim group-level data analysis of its phase 1b trial of IMU-935 in patients with moderate-to-severe psoriasis. The interim analysis revealed that…
Analyst Bullish On SQZ Biotech’s Technology For Solving Cell Therapy Challenges – SQZ Biotechnologies (NYSE:SQZ)
[ad_1] HC Wainwright initiated coverage on SQZ Biotechnologies Company SQZ with a Buy rating and a price target of $10. SQZ is focused on developing novel therapeutic cell therapy platforms centering around…
Reaction Is Overdone For PTC Therapeutics Pausing Huntington Trial Enrollment, Analyst Says – PTC Therapeutics (NASDAQ:PTCT)
[ad_1] Earlier today, the FDA requested additional data to allow a 12-week portion of the Phase 2 PIVOT-HD study evaluating PTC Therapeutics Inc’s PTCT PTC518 for Huntington’s disease. The additional requirement…
PTC Therapeutics Pauses Enrollment In Huntington’s Candidate Trial In US – PTC Therapeutics (NASDAQ:PTCT)
[ad_1] PTC Therapeutics Inc PTCT confirmed that enrollment is active and ongoing for its Phase 2 PIVOT-HD trial of PTC518 for Huntington’s disease at study sites globally. The Phase 2…
Roche Posts Lower Quarterly Sales As Demand For COVID Products Slide – Roche Holding (OTC:RHHBF), Roche Holding (OTC:RHHVF), Roche Holding (OTC:RHHBY)
[ad_1] Roche Holdings AG RHHBY Q3 FY22 sales reached CHF14.74 billion, down 6% Y/Y due to lower sales from COVID-19 treatments and diagnostics. “The third quarter of 2022 was particularly challenging…
Analyst Sees A Leader In Solid Tumor Cell Therapy In This Stock – Lyell Immunopharma (NASDAQ:LYEL)
[ad_1] HC Wainwright initiated coverage of Lyell Immunopharma Inc LYEL with a Buy rating and a price target of $12 per share. Lyell leverages two ex vivo epigenetic reprogramming technologies, Gen-R and…
Sage Therapeutics/Biogen Highlight Additional Data From Depression Candidate – Sage Therapeutics (NASDAQ:SAGE), Biogen (NASDAQ:BIIB)
[ad_1] Sage Therapeutics Inc SAGE and Biogen Inc BIIB presented additional data from the Phase 3 SKYLARK Study of zuranolone in adult women with postpartum depression (PPD). The SKYLARK Study, as previously reported,…
Daré Bioscience’s Intravaginal Ring Improves Vasomotor, Vaginal Symptoms Of Menopause – Dare Bioscience (NASDAQ:DARE)
[ad_1] Daré Bioscience Inc DARE announced topline efficacy results from its Phase 1/2 trial of DARE-HRT1. DARE-HRT1 is a novel, investigational intravaginal ring (IVR) designed to deliver bio-identical 17β-estradiol and bio-identical…
Broadcom Seeks Early European Approval For VMware’s $61B Buyout – Broadcom (NASDAQ:AVGO)
[ad_1] In a bid to diversify its business into enterprise software, U.S. chipmaker Broadcom Inc AVGO agreed in May to acquire cloud computing company VMware Inc VMW for $61 billion. The company is…
News Corp and Fox Corp’s Possible Consolidation, Faster Lead Times For iPhone 14 Models, Kanye West Buys Conservative Social Media Platform, Twitter Prepares Tackling Spread Of Misinformation: Top Stories Monday, Oct. 17 – Apple (NASDAQ:AAPL), Albertsons Companies (NYSE:ACI)
[ad_1] Wall Street Journal Rupert Murdoch Explores News Corp and Fox Corp Consolidation Rupert Murdoch weighed merging his media empire, News Corp NWSA and Fox Corp FOX, nearly a…
Pasithea’ Largest Investor Group Says AlloMek Therapeutics Deal Ill-timed, Highly Dilutive – Pasithea Therapeutics (NASDAQ:KTTA)
[ad_1] Investor group comprising Camac Partners LLC, Concord Investment Partners Ltd, and Leonite Capital LLC condemned Pasithea Therapeutics Corp’s KTTA recently announced the acquisition of AlloMek Therapeutics LLC. The investors, collectively the largest stockholder of…
Biden Asked OPEC+ To Delay Output Decision, Elon Musk Faces Federal Probe Over Twitter Deal, Netflix Ad-Supported Plan: Top Stories Friday, Oct. 14 – Bitcoin (BTC/USD), Ethereum (ETH/USD)
[ad_1] Reuters Twitter Says Elon Musk Under Federal Probe Over $44B Twitter Deal, In Court Filing Tesla Inc TSLA CEO Elon Musk is reportedly under investigation by federal authorities…
Inovio Pharma Highlights Early Data From Experimental Drug For Respiratory Tract Disease – Inovio Pharmaceuticals (NASDAQ:INO)
[ad_1] Inovio Pharmaceuticals Inc INO announced interim results from an ongoing Phase 1/2 trial evaluating INO-3107 for HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) in adults. RRP is caused…
FDA Signals Shortage For Teva Pharma’s ADHD Drug Due To Manufacturing Delay – Teva Pharmaceutical Indus (NYSE:TEVA)
[ad_1] The FDA said that there was a shortage of Adderall after intermittent manufacturing delays at Teva Pharmaceutical Industries Ltd TEVA. Adderall is indicated to treat Attention Deficit Hyperactivity Disorder…
Moderna In-Licenses Autolus’ Technology For mRNA-Based Cancer Therapeutics – Autolus Therapeutics (NASDAQ:AUTL)
[ad_1] Moderna Inc MRNA has exercised its option to license Autolus Therapeutics plc’s AUTL proprietary binders against an undisclosed immuno-oncology target for the development and commercialization of mRNA therapeutics. This follows an…
Joe Biden Vows Consequences Against Saudi Arabia, Philips Warns Lower Sales & Profit, Intel Explores Substantial Job Cuts: Top Stories Wednesday, Oct. 12 – Bitcoin (BTC/USD), Ethereum (ETH/USD)
[ad_1] Reuters Joe Biden Says Saudi Arabia Will Face’ Consequences For What They’ve Done With Russia’ President Joe Biden has reportedly said there would be “consequences” for Saudi Arabia…
Roche To Introduce Next-Generation Portfolio Of COVID-19 Rapid Tests – Roche Holding (OTC:RHHBF), Roche Holding (OTC:RHHVF), Roche Holding (OTC:RHHBY)
[ad_1] Roche Holdings AG RHHBY has announced the launch of its next-generation portfolio of COVID-19 rapid antigen tests (2.0) for self-testing and professional use in countries accepting the CE Mark. Distribution…
Honda, LG Energy Solution Join Forces To Setup $4.4B Battery Plant In Ohio – Honda Motor Co (NYSE:HMC)
[ad_1] Honda Motor Co Ltd HMC and LG Energy Solution have selected Ohio to build their battery plant with an investment of $4.4 billion. The two companies announced the plan in August…
Boeing Reports Increased Orders, Deliveries In September – Boeing (NYSE:BA)
[ad_1] Boeing Co’s BA deliveries rose in September to 51 airplanes, while orders rose by 90. Last month, Boeing had 51 new 737 MAX airplane orders and 45 widebody airplanes, including…
Illumina Inks AI Pact With AstraZeneca To Accelerate Drug Target Discovery – AstraZeneca (NASDAQ:AZN), AstraZeneca (OTC:AZNCF)
[ad_1] Illumina Inc ILMN entered a strategic research collaboration with AstraZeneca plc AZN on drug target discovery. Financial and other details of the partnership were not disclosed. Under the terms of the agreement,…
DICE Therapeutics Stock Doubles After Positive Data From Lead Psoriasis Candidate – DICE Therapeutics (NASDAQ:DICE)
[ad_1] DICE Therapeutics Inc DICE has announced positive topline data from its Phase 1 trial of DC-806, an oral small molecule antagonist of the pro-inflammatory cytokine IL-17. Following four weeks of…
Twitter May Drop Clickable Hashtags, AstraZeneca’s Nasal COVID-19 Vaccine Fails Trial, Coinbase Gets Singapore Nod: Top Stories Tuesday, Oct. 11 – Coinbase Global (NASDAQ:COIN)
[ad_1] Reuters US-China Chip War: KLA Relaxes Chip Supply To China U.S. chipmaker KLA Corp’s KLAC legal department emailed China informing that it shall stop sales and service to…
Janssen Touts Encouraging Data From Two Ulcerative Colitis Treatments – Johnson & Johnson (NYSE:JNJ)
[ad_1] Janssen Pharmaceutical, a unit of Johnson & Johnson JNJ, announced data from an ongoing analysis of a Phase 2a trial of guselkumab and golimumab combo therapy for ulcerative colitis. The results…